Institute of Experimental Medicine, VA. Almazov Federal Heart, Blood and Endocrinology Center, St-Petersburg, Russian Federation.
Int J Nanomedicine. 2010 Apr 7;5:231-7. doi: 10.2147/ijn.s8719.
The clinical outcome of patients with ischemic heart disease can be significantly improved with the implementation of targeted drug delivery into the ischemic myocardium. In this paper, we present our original findings relevant to the problem of therapeutic heart targeting with use of nanoparticles. Experimental approaches included fabrication of carbon and silica nanoparticles, their characterization and surface modification. The acute hemodynamic effects of nanoparticle formulation as well as nanoparticle biodistribution were studied in male Wistar rats. Carbon and silica nanoparticles are nontoxic materials that can be used as carriers for heart-targeted drug delivery. Concepts of passive and active targeting can be applied to the development of targeted drug delivery to the ischemic myocardial cells. Provided that ischemic heart-targeted drug delivery can be proved to be safe and efficient, the results of this research may contribute to the development of new technologies in the pharmaceutical industry.
通过将靶向药物递送至缺血心肌,可以显著改善缺血性心脏病患者的临床预后。本文介绍了我们在使用纳米颗粒进行治疗性心脏靶向方面的原始发现。实验方法包括制备碳纳米颗粒和硅纳米颗粒、对其进行表征和表面修饰。在雄性 Wistar 大鼠中研究了纳米颗粒制剂的急性血液动力学效应和纳米颗粒的体内分布。碳纳米颗粒和硅纳米颗粒是无毒材料,可用作心脏靶向药物递送的载体。被动靶向和主动靶向的概念可应用于开发针对缺血心肌细胞的靶向药物递送。如果可以证明缺血性心脏靶向药物递送是安全有效的,那么本研究的结果可能有助于制药行业新技术的发展。